Prostate

Article	Citations
Urethral luminal epithelia are castration‐insensitive cells of the proximal prostate	53
High intratumoral CD8+ T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy	41
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume	38
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial	35
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement	33
Antitumor efficacy of interferon‐γ‐modified exosomal vaccine in prostate cancer	33
ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis	29
Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer	28
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform	28
Escherichia coli, a common constituent of benign prostate hyperplasia‐associated microbiota induces inflammation and DNA damage in prostate epithelial cells	26
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer	25
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment	25
Validation of a prostate cancer polygenic risk score	23
Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer	22
miR‐30a inhibits androgen‐independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4	21
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications	21
SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)	21
Zonal regulation of collagen‐type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry	20
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis	20
Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance	20
Clinical and genomic features of SPOP‐mutant prostate cancer	20
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment	19
Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia	19
Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia	18
Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells	18

Patterns of stemness‐associated markers in the development of castration‐resistant prostate cancer	18
Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance	18
Selenium‐binding protein 1 alters energy metabolism in prostate cancer cells	18
THBS4 silencing regulates the cancer stem cell‐like properties in prostate cancer via blocking the PI3K/Akt pathway	18
Real‐world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes	18
225Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis	18
Barriers and facilitators of germline genetic evaluation for prostate cancer	18
A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance	17
Abnormal gut microbiota composition is associated with experimental autoimmune prostatitis‐induced depressive‐like behaviors in mice	16
Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy	15
Prostate cancer detection rate in men undergoing transperineal template‐guided saturation and targeted prostate biopsy	15
Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities	15
Circular RNA circANKS1B acts as a sponge for miR‐152‐3p and promotes prostate cancer progression by upregulating TGF‐α expression	15
Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors	15
Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores	15
Cancer‐driven IgG promotes the development of prostate cancer though the SOX2‐CIgG pathway	15
Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer	14
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients	14
PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence	14
Twenty‐year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort	14
Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients	14
Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis	13
Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy	13
Current and projected number of years of life lost due to prostate cancer: A global study	13
Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial–mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway	13
PSMA‐positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state	13
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities	13
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting	13
The effect of lymph node dissection on cancer‐specific survival in salvage radical prostatectomy patients	13
Prostate‐to‐bladder cross‐sensitization in a model of zymosan‐induced chronic pelvic pain syndrome in rats	12
CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion	12
Does screening for prostate cancer improve cancer‐specific mortality in Asian men? Real‐world data in Yokosuka City 15 years after introducing PSA‐based population screening	12
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study	12
Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins	12
Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1‐dependent inhibition of the NLRP3 inflammasome in an EAP mouse model	12
Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer	12
Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)	11
Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy	11
Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing t	11
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD‐L1 expression by C5a	11
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients	11
Effect of Eriocalyxin B on prostatic inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis	11
Knowledge of prostate cancer among African American men: A systematic review	11
Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy	10
Protein signatures to distinguish aggressive from indolent prostate cancer	10
Single‐port versus multiport robotic‐assisted radical prostatectomy: A systematic review and meta‐analysis on the da Vinci SP platform	10
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations	10
Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo	10
Observed evidence for guideline‐recommended genes in predicting prostate cancer risk from a large population‐based cohort	10
Optimizing the management of castration‐resistant prostate cancer patients: A practical guide for clinicians	10

Brazilian berry extract (Myrciaria jaboticaba): A promising therapy to minimize prostatic inflammation and oxidative stress	10
Early‐onset prostate cancer is associated with increased risks of disease progression and cancer‐specific mortality	10
Gonadotropin‐releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin‐releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study	10
Stromal cell interplay in prostate development, physiology, and pathological conditions	10
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer	10
Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis	10
Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models	10
Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancer	10
The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms	10
Plasma IL‐6 and TNF‐α levels correlate significantly with grading changes in localized prostate cancer	10
Inhibition of neurogenic and thromboxane A2‐induced human prostate smooth muscle contraction by the integrin α2β1 inhibitor BTT‐3033 and the integrin‐linked kinase inhibitor Cpd22	10
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer	9
Mismatch repair deficiency and clinical implications in prostate cancer	9
Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer	9
Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG‐negative prostate cancer	9
Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer	9
Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone‐sensitive prostate cancer	9
Prostate tumors of native men from West Africa show biologically distinct pathways—A comparative genomic study	9
Differential impact of paired patient‐derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture	9
Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test	9
Tight junction protein claudin‐1 is downregulated by TGF‐β1 via MEK signaling in benign prostatic epithelial cells	9
Evaluating post radical prostatectomy mechanisms of early continence	9
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index	9
Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis	9
miR‐196a‐mediated downregulation of p27kip1 protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy	9
Promotion of epithelial hyperplasia by interleukin‐8—CXCR axis in human prostate	9
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer	8
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration‐resistant prostate cancer cells via altering androgen receptor‐lectin‐like transcript 1 signals	8
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer	8
Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins	8
M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin‐like growth factor 1 knockdown	8
Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation	8
The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers	8
Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient‐derived primary prostate cells	8
Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling	8
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association	8
SIRT3 affects mitochondrial metabolic reprogramming via the AMPK–PGC‐1α axis in the development of benign prostatic hyperplasia	8
Paracrine Wnt signaling is necessary for prostate epithelial proliferation	8
18F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer	8
Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer	8
CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer	8
CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage	8
Spatial and temporal patterns of prostate cancer burden and their association with Socio‐Demographic Index in Asia, 1990–2019	8
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long‐term follow‐up study	7
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer	7
Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer	7
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients	7
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence	7
Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial	7
Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants	7
Therapeutic effects of nerve growth factor‐targeting therapy on bladder overactivity in rats with prostatic inflammation	7
Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level	7
MRI‐detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern	7
A hemi‐spleen injection model of liver metastasis for prostate cancer	7
Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno‐geographic variations	7
Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients	7
Role of Runx2 in prostate development and stem cell function	7
DNA‐PKc inhibition overcomes taxane resistance by promoting taxane‐induced DNA damage in prostate cancer cells	7
Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5‐alpha reductase inhibitor treated human benign prostate hyperplasia patients	7
Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?	7
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis	7
β2‐adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog‐Gli1 signaling activation	7
The evolving landscape of prostate cancer somatic mutations	7
RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer	7
Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms	7
STAT3 phosphorylation is required for the HepaCAM‐mediated inhibition of castration‐resistant prostate cancer cell viability and metastasis	7
Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy	7
Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis	7
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA‐related parameters to enhance the detection of clinically significant cancer across different region	7
Germline genetics of prostate cancer	7
Postoperative peripheral neuropathies associated with patient positioning during robot‐assisted laparoscopic radical prostatectomy (RARP): A systematic review of the literature	6
Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data	6
Impact of therapy on cancer metabolism in high‐risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy	6
Influence of pelvic lymph node dissection and node‐positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer	6
Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism‐related genes act as prognostic signatures for prostate cancer	6
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer	6
Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings	6
Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga‐PSMA‐PET/CT in prostate cancer patients candidate to definitive radiotherapy	6
Long‐term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence	6
Rates and trends in stage‐specific prostate cancer incidence by age and race/ethnicity, 2000–2017	6

Transcript analysis of commercial prostate cancer risk stratification panels in hard‐to‐predict grade group 2–4 prostate cancers	6
Prevalence of prostate cancer at autopsy in Nigeria—A preliminary report	6
Increased nuclear factor I/B expression in prostate cancer correlates with AR expression	6
Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells	6
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer	6
Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study	6
Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer	6
Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer	6
Risk of major adverse cardiovascular events among second‐line hormonal therapy for metastatic castration‐resistant prostate cancer: A real‐world evidence study	6
Machine learning algorithms can more efficiently predict biochemical recurrence after robot‐assisted radical prostatectomy	6
Combination with vorinostat enhances the antitumor activity of cisplatin in castration‐resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH	6
A new flavonoid derivative exerts antitumor effects against androgen‐sensitive to cabazitaxel‐resistant prostate cancer cells	6
The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot‐assisted laparoscopic radical prostatectomy	6
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel‐resistant prostate cancer	6
Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides	6
A novel immunocompetent model of metastatic prostate cancer‐induced bone pain	6
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6‐mediated Axl and RON signaling	5
Metagenomics studies for the diagnosis and treatment of prostate cancer	5
Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics	5
Identification of novel susceptibility factors related to CP/CPPS‐like symptoms: Evidence from a multicenter case‐control study	5
The effect of primary urological cancers on survival in men with secondary prostate cancer	5
TALEN‐mediated generation of Nkx3.1 knockout rat model	5
Artificial intelligence trained with integration of multiparametric MR‐US imaging data and fusion biopsy trajectory‐proven pathology data for 3D prediction of prostate cancer: A proof‐of‐concept study	5
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms	5
High‐intensity interval training attenuates the effects caused by arterial hypertension in the ventral prostate	5
Sociodemographic index and global trends in prostate cancer: 1990–2017	5
Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI‐algorithm for lesion detection and classification	5
Smoothened loss is a characteristic of neuroendocrine prostate cancer	5
Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experience	5
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients	5
MEX3D is an oncogenic driver in prostate cancer	5
Contemporary seminal vesicle invasion rates in NCCN high‐risk prostate cancer patients	5
Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7	5
The role of transurethral resection of prostate (TURP) in patients with underactive bladder: 12 months follow‐up in different grades of detrusor contractility	5
Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population	5
Bipolar androgen therapy (BAT): A patient's guide	5
Comparison between 18F‐DCFPyL PET and MRI for the detection of transition zone prostate cancer	5
Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software‐based systems	5
Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer	5
Comparing two different low‐intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two‐arm, parallel‐group randomized controlled trial	5
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series	5
Application of European‐specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations	5
Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro‐oncology registry	5
The influence of low‐carbohydrate diets on the metabolic response to androgen‐deprivation therapy in prostate cancer	5
Development of a novel castration‐resistant orthotopic prostate cancer model in New Zealand White rabbit	5
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapy	5
Spine metastasis in patients with prostate cancer: Survival prognosis assessment	5